RxDoctor Payments Data

Ali Amini, MD

Gastroenterology · Milford, MANPI 1962502997

Payments from drug & device makers

$5,415in general payments, 2019–2025

Across 244 payments — averaging $22.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Braintree Laboratories, Inc.$649
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$545
  • Intercept Pharmaceuticals, Inc.$137
  • Covidien LP$114
  • Takeda Pharmaceuticals U.S.A., Inc.$112
  • plus $811 from 16 others

What the payments were for

  • Food & beverage$4,76588%
  • Gifts$64912%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,415 in reported general payments places this provider in the 70th percentile of 579 gastroenterology providers in Massachusetts.

See all gastroenterology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$147,010
Medicare patients
556
Services billed
1,246

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide38$39,874
Ursodiol30$9,388
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag34$4,193
Omeprazole186$3,290
Mesalamine DrMesalamine22$2,783
Mercaptopurine19$2,553
Mesalamine11$2,244
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C15$2,156
Famotidine58$1,446
Pantoprazole Sodium60$1,196
CholestyramineCholestyramine (With Sugar)11$617
Sulfasalazine15$451
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip12$306
Metoclopramide Hcl12$63

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$3,046$39,87438 claims
Braintree Laboratories, Inc.Suflave$649$4,19334 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu$545$2,15615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 579 gastroenterology providers in Massachusetts.

Other gastroenterology in Milford

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →